US 2024/0041833 A1 · PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER

Abstract

The present invention relates to pharmaceutical products and in particular to pharmaceutical combination products. The invention further relates to uses of such products in medical treatment. Embodiments of the invention have been particularly developed as pharmaceutical combination products of a protoparvovirus and an antiviral benzimidazole derivative or a pharmaceutically acceptable salt or prodrug of the benzimidazole derivative for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

Claims15

Dependent claims

A pharmaceutical combination product comprising:

(a) a protoparvovirus, wherein said protoparvovirus is H-1 (H-1PV) or a related rodent protoparvovirus selected from LuIII, Mouse minute virus (MMV), Mouse protoparvovirus (MPV), Rat minute virus (RMV), Rat protoparvovirus (RPV) or Rat virus (RV);
and
(b) an antiviral benzimidazole derivative of Formula I:
or a pharmaceutically acceptable salt or prodrug thereof,
wherein, in the antiviral benzimidazole derivative of Formula I:
M is a 5-membered heteroaryl ring;
and
A′ and A″ are each independently selected from any one of (A1) to (A17):
wherein R is hydrogen or methyl.

6 more elements

Dependencies are inferred from the claim text.

Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer

Life of this patent

Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer

Life of this patent

Abstract

Claims15